|
 |
| home > ict > Spring 2008 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. ICT provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of ICT |
 |
| |
|
|
|
| Raising the Bar for patient recruitment methods has included the use of a comprehensive in-house database covering a wide range of countries and therapeutic indications.This method, which is increasingly being used by CROs, involves a more scientific and targeted approach and should become a new standard for best practice within the industry, argues Alan Morgan of ICON Clinical Research |
|
|
| Challenging current paradigms associated with automated cognitive testing within clinical trials,Mark Cusack of CDR looks at ways to employ the appropriate systems that can provide the industry with greater operational efficiencies, scientific insight, and Brain Power |
|
|
| The creation of data monitoring committees is almost a routine practice in randomised control trials that are performed specifically to register a human medicinal product. In Credible Risk Management, Gurdyal Kalsi of MDS Pharma Services assesses the value of data monitoring committees from the perspective of a CRO |
|
|
|
|
| Global consolidation within the pharmaceutical industry is becoming increasingly necessary in the current economic climate. In Solid Supply, Chris Tierney at DHL Excel Supply Chain examines this shift alongside the need for cost reduction and service enhancement in what is a highly competitive industry |
|
|
|
| In The Fibrotic Process, William Rosenberg of University College London assesses the worldwide impact of chronic viral hepatitis, alcoholic liver disease and non-alcoholic fatty liver disease on the pharmaceutical and biotechnology industries in terms of their earning potential for new therapeutic interventions and diagnostic tests |
|
|
| As sleep medicine makes its mark on drug development in the pharmaceutical industry, Martin King of LCG Bioscience outlines some of the most common sleep disorders and their implications, and explains the techniques available for practitioners undertaking specialist sleep trials, in More Than a Sleeping Partner |
|
|
|
| David Edwards of Capsugel assesses the teething problems faced by those trying to introduce new drugs into the marketplace. The restriction of resources in early stage drug development, such as available drug quantities, testing personnel, equipment, funding and, perhaps most crucially, time, are all considered in Beyond Fast Filling |
|
|
|
| The success of a trial, and ultimately clean study data, is determined during the initial stages of the process. In Sound Starts, Frank Dunn and Jeffery Bowden of Biomedical Systems discuss the question of logistics, and assess the safety and efficacy of a particular drug or medical device used in clinical trials |
|
|
| In Expect the Unexpected, Oliver Bohnsack and Manuela Lesch of Perceptive Informatics assert that in order to advance the procedure of clinical trials, dramatic improvements within medical imaging technologies are vital, as is the need to regularly review those directly involved in conducting the trials in order to provide consistent results |
|
|
|
| As the outsourcing scene opens up to emerging markets, pharmaceutical companies must make decisions about which of the key regions to focus on when it comes to clinical trials. Jerry Boxall of ACM-Pivotal Europe gets on the trail in Materialising Markets |
|
|
| Jaime Caro of United BioSource Corporation considers how Surmounting the Hurdles of New German Regulations will mean that companies can no longer leave the economics to Phase IV – early preparation is called for |
|
|
| In The Global Player, Nilesh Vite and Arulsingh Jayaraman of Lambda Therapeutic Research assess India’s role as a burgeoning player for the outsourcing of clinical trials,placing the focus on efficient subject recruitment and effective cost management |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
__________________________
__________________________
__________________________
__________________________
|
